Trials / Completed
CompletedNCT07484074
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- Ollin Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Detailed description
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faricimab | Intravitreal Injection |
| DRUG | OLN324 | Intravitreal Injection |
Timeline
- Start date
- 2025-02-12
- Primary completion
- 2025-10-10
- Completion
- 2025-12-09
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Locations
30 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07484074. Inclusion in this directory is not an endorsement.